CTX 110, CTX120, and CTX130 are being developed as immunotherapies, which, respectively, create allogenic CAR-T cells against CD19 for B-cell malignancies, BCMA for multiple myeloma, and CD70 for both hematologic cancers (certain lymphomas) and solid tumors (renal cell carcinoma) (Immuno-Oncology – CRISPR, 2019b). Here, CD19 is linked to lymphoma.